News and Announcements
Anteo Signs Licensing Agreement with Leading Life Science Company
- Published March 13, 2012 11:41AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
13 March 2012: Anteo Diagnostics Limited (ASX:ADO) is pleased to announce that it has signed a Patent and Technoology License Agreement with eBioesence, a leading US headquartered Life Sciences Company, providing with access to Anteo’s unique Mix&Go technology.
Under the terms of the Agreement, Anteo will supply Mix&Go for the use in the manufacture of biological reagents for all the applicable markets in which the company operates. Anteo will receive an initial upfront payment, fixed revenue for Mix&Go reagent supplied, and a royalty fee paid quarterly based on a percentage of worldwide net sales.
——
To view the full article, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
